The LDN 3: To Purchase with discounts before 1st September 2022 Go to ldnresearchtrust.org/ldn-book-3 for full details

Linda Elsegood: Welcome to the LDN radio show brought to you by the LDN Research Trust I'm your host, Linda Elsegood. I have an exciting lineup of guest speakers who are LDN experts in their field. We will be discussing low-dose naltrexone and its many uses in autoimmune diseases, cancers, etc. Thank you for joining us.

This was an LDN Radio Show interview in 2022.

Linda Elsegood: Welcome to the LDN Radio Show, brought to you by the LDN Research Trust I'm your host, Linda Elsegood. I have an exciting lineup of guest speakers who are LDN experts in their field. We will be discussing low-dose naltrexone and its many uses in autoimmune diseases, cancers, etc. Thank you for joining us.

The role of immune modulation and anti-inflammatory agents in the management of prostate cancer: A case report of six patients

Oncol Lett
07 June 2022
https://pubmed.ncbi.nlm.nih.gov/35761946/

Tim - England: Eye cancer (2022) (LDN; low dose naltrexone)

Antagonists of the Mu-Opioid Receptor in the Cancer Patient: Fact or Fiction?

Curr Oncol Rep
01 June 2022
https://pubmed.ncbi.nlm.nih.gov/35648340/

LDN Webinar Presentation 18 May 2022: Dr Masoud Rashidi - LDN, Dosing, Fillers and Compounded Options. LDN, ULDN and Pain/Opioid Issues

Sponsored by Innovative Compounding Pharmacy https://icpfolsom.com/